Anxiety Treatment Market Set for Explosive Growth, Poised to Hit $4.26 Billion by 2033

March 05, 2026 12:01:56 pm

Source: PRISM News

2026-03-05 12:01:56 ET

AI Enhanced Photo*

The market for treatments targeting Generalized Anxiety Disorder (GAD) is entering a strong growth phase. Analysts expect the market to expand from $1.8 billion in 2023 to more than $4.26 billion by 2033. This represents a compound annual growth rate of roughly 9%.

Several factors are driving this growth. First, awareness of mental health conditions continues to rise. At the same time, more patients are seeking treatment for anxiety-related disorders. As a result, demand for both pharmaceutical and non-pharmaceutical therapies continues to increase.

Rising Demand for Anxiety Treatments

Traditionally, physicians have relied on anti-anxiety medications and antidepressants to treat GAD. However, treatment strategies are evolving. Patients and clinicians are now incorporating additional therapeutic approaches.

For example, cognitive behavioral therapy (CBT) and mindfulness-based techniques have gained popularity. These methods help patients develop coping skills and manage symptoms without relying entirely on medication.

In addition, digital health tools are expanding access to treatment. Telehealth platforms, mental health apps, and virtual therapy sessions allow patients to connect with providers more easily. Consequently, individuals in remote areas or those who prefer virtual care now have more treatment options.

Helus Pharma Advances a New GAD Therapy

Meanwhile, Helus Pharma is working to develop a new treatment option for patients who do not respond well to existing therapies.

Recently, the company announced promising topline results from a Phase 2 signal detection study evaluating HLP004, a serotonergic agonist designed for moderate-to-severe GAD. The study focused on patients who remained symptomatic despite ongoing standard-of-care antidepressant treatment.

Importantly, the results showed meaningful clinical improvements.

Key findings from the study include:

A 10.4-point reduction on the Hamilton Anxiety Rating Scale (HAM-A) after six weeks for patients receiving 20 mg of HLP004 alongside standard therapy (p < 0.0001).
67% of patients responded to the treatment, while 39% achieved remission at six months.
The therapy involved a short in-clinic treatment session, with acute effects lasting about 90 minutes and patients discharged within three hours.
The drug also demonstrated a favorable safety profile, with no drug-related serious adverse events or suicidality-related signals.

According to Andrew Cutle r , Clinical Professor of Psychiatry at SUNY Upstate Medical University , the results are encouraging.

"The magnitude of improvement observed over standard-of-care treatments, combined with the rapid onset and short in-clinic treatment experience, is highly encouraging for this underserved patient population," Cutler said.

Furthermore, Michael Cola , CEO of Helus Pharma, emphasized the ongoing need for new treatment options.

"Many patients continue to struggle despite currently available therapies," Cola said. "These data highlight the potential of HLP004 to bring hope to GAD patients."

Looking ahead, the company also plans to release data for HLP003, its investigational therapy for major depressive disorder, in Q4 2026.

Innovation Expands Across the Mental Health Sector

At the same time, innovation is accelerating across the broader mental health market. In fact, analysts believe the overall anxiety treatment sector could reach $12 billion to $17 billion within the next decade.

Several companies are contributing to this progress.

For instance, Johnson & Johnson recently presented 11 research abstracts at the American College of Neuropsychopharmacology Annual Meeting. These presentations highlighted advancements in treatments for depression, schizophrenia, and bipolar disorder.

Meanwhile, BrainsWay Ltd. introduced an accelerated treatment protocol for major depressive disorder using its FDA-cleared SWIFT(TM) Deep Transcranial Magnetic Stimulation (Deep TMS(TM)) technology. Notably, this protocol reduces the traditional 20-session treatment schedule to just six half-day sessions , followed by weekly maintenance visits.

In addition, Firefly Neuroscience, Inc . recently reported significant commercial expansion after acquiring Evoke Neuroscience, Inc. . Following the acquisition, the company recorded a 20-fold increase in its commercial footprint and a 33-fold rise in EEG/ERP scan volumes .

Outlook for the Anxiety Treatment Market

Overall, the outlook for the anxiety treatment market remains strong. Growing awareness of mental health conditions continues to drive demand for new therapies.

Moreover, advances in neuroscience, pharmaceuticals, and digital health technologies are expanding treatment possibilities. As a result, patients now have more options than ever before.

Ultimately, the push to innovate in anxiety treatment goes beyond market growth. It also represents a broader effort to improve care for millions of people living with anxiety disorders around the world.